戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ns are necessary to confer specificity for S-mephenytoin.
2 ymmetric synthesis of the anticonvulsant (R)-mephenytoin.
3  barbiturates, and the prototype substrate S-mephenytoin.
4  proteins required to convert CYP2C9 to an S-mephenytoin 4'-hydroxylase (6% of the activity of wild-t
5 ree amino acids did not confer significant S-mephenytoin 4'-hydroxylase activity to P450 2C9, althoug
6 he N-terminal portion of helix I conferred S-mephenytoin 4'-hydroxylation activity with a K(M) simila
7 286N, V292A, and F295L, were essential for S-mephenytoin 4'-hydroxylation activity.
8 ining the specificity of human CYP2C19 for S-mephenytoin 4'-hydroxylation, we constructed chimeras by
9 so failed to stimulate CYP2C19-catalyzed (S)-mephenytoin 4-hydroxylation, whereas the E48G/E49G doubl
10  2C19 is selective for 4'-hydroxylation of S-mephenytoin and 5-hydroxylation of omeprazole, while the
11  activity was assessed using the probe drugs mephenytoin (CYP-2C19), chlorzoxazone (CYP-2E1), dapsone
12 egard to inhibition of CYP2C19-catalyzed (S)-mephenytoin hydroxylation in human liver microsomes.
13                            Chlorzoxazone and mephenytoin metabolism correlated with the multiple orga
14                                              Mephenytoin metabolism was profoundly suppressed after i
15 sis of two bioactive compounds, nirvanol and mephenytoin, was carried out.
16 9 is selective for the 4'-hydroxylation of S-mephenytoin while the highly similar CYP2C9 has little a